CORT terminated its exclusive specialty pharmacy partnership with Optime Care and transitioned services to Curant Health while experiencing a substantial decline in operating income despite revenue growth.
The termination of the long-standing Optime Care exclusive arrangement represents a significant operational shift that could impact patient access and distribution efficiency. The disconnect between growing revenue and sharply declining operating margins suggests either integration costs from the pharmacy transition or other operational challenges that warrant close monitoring.
Revenue grew a healthy 12.8% to $761.4M, but this positive top-line performance was overshadowed by operating income declining substantially due to meaningfully higher SG&A expenses that grew to $448.7M. Despite the operational headwinds, the company maintained a strong balance sheet with modest increases in liabilities and receivables. The dramatic reduction in capital expenditures to just $211K suggests either deferred investments or completion of a major spending cycle.
Capex reduced 90.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
SG&A up 60.1% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Net income declined 29.4% — review whether driven by operations, interest costs, or non-recurring items.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Current liabilities rose 18% — increased short-term obligations, watch current ratio.
Liabilities increased 17.3% — monitor debt-to-equity ratio and interest coverage.
Revenue growing 12.8% — solid top-line momentum, watch margins for quality of growth.
Receivables grew 10.8% — monitor days sales outstanding for collection efficiency.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →